Arrivent Biopharma Inc

AVBP remains in a Stage 2 corrective advance within a broader uptrend, maintaining higher highs and lows. After a recent pullback into the 9/20 EMA and 50 DMA support zone, price has shown initial absorption. Medium-term bias is Bullish, but short-term timing suggests patience as consolidation continues around key moving averages. The speculative strategy calls for selective participation on pullback interactions near these support areas.

• ↑100% Buy ratings, $44.83 average target signals 33% upside.
• ↑Stock gained 45% since Mar 31 on Phase 3 trial anticipation.
• ↓Negative earnings yield and $160.6 M net loss imply weak profitability.